- Case Report
- Open Access
Clozapine induced pancytopenia leading to severe sepsis: an unusual early complication
BMC Research Notesvolume 8, Article number: 792 (2015)
Clozapine is a second generation antipsychotic used to treat resistant schizophrenia and other psychotic illnesses. Leucopenia or agranulocytosis is a rare side effect of this drug. Pancytopenia is an extremely rare side effect of clozapine and literature review showed only one such case in where the pancytopenia developed several months after starting clozapine together with other antipsychotic drugs.
A 26-year-old Sri Lankan male was admitted with fever for 3 days. Apart from generalized body aches there were no other significant symptoms. His blood counts showed pancytopenia. He was being treated for a resistant schizophrenia and clozapine was started only 4 weeks before. Common causes for pancytopenia were excluded, and a diagnosis of clozapine induced pancytopenia was made. He was managed in the intensive care unit with broad spectrum antibiotics, antifungals and granulocyte colony stimulating factors. He made a complete recovery after 4 weeks.
This is a rare and probably the first reported case of early onset clozapine induced pancytopenia complicated by severe sepsis recovering completely.
Clozapine is an atypical antipsychotic drug. It relieves both negative and positive symptoms of schizophrenia and is the drug of choice in resistant schizophrenia [1, 2]. Clozapine causes leucopenia or agranulocytosis as a rare side effect. Clozapine induced pancytopenia is even rarer than leucopenia and review of literature showed only one published case. Agranulocytosis is defined as granulocyte count of <0.5 × 103/µl, and leukopenia is defined as white blood cell (WBC) count of <3.5 × 103/µl. The causes for the blood dyscrasias are believed to be due to idiosyncratic (type B) reactions, immune-mediated or toxic suppression of hemopoietic precursors due to prolonged administration . In our patient early occurrence of pancytopenia is most likely due to an idiosyncratic drug reaction.
A 26-year-old Sri Lankan male was admitted to hospital with fever for 3 days and body aches. He did not have any other significant symptoms. He was diagnosed of having schizophrenia 4 years ago and was attending a psychiatric clinic. He was started on clozapine, 4 weeks ago (200 mg daily), because of inadequate control of symptoms with conventional antipsychotics. On examination he was febrile (102 °F), not pale or icteric. He did not have lymphadenopathy. Blood pressure was 130/80 mmHg and pulse rate was 110 bpm with good volume. His respiratory rate was 32 cycles per minute. Examination of the abdomen, cardiovascular and respiratory systems were unremarkable.
His full blood count (FBC), which was done a day prior to hospital admission showed white blood cell count (WBC) 2.9 × 103/µl, absolute neutrophil count 667/µl (23 %), lymphocytes 2117/µl (73 %), Hemoglobin (Hb) 11.3 g/dl, platelet 188 × 103/µl. The first FBC during the hospital stay showed reduced blood counts, of which WBC 0.2 × 103/µl with absolute neutrophil count (ANC) 110/µl, lymphocyte count 80/µl, Hb 12.2 g/dl and platelet 972 × 103/µl. The C reactive protein was (CRP) 270 mg/L (<6 mg/L). His chest X ray, ultrasound scan (USS) of abdomen and pelvis, urine full report was normal. Serology for dengue virus, human immunodeficiency virus and parvo B19 virus were negative. Electrocardiogram (ECG) showed sinus tachycardia.
Clinical diagnosis of neutropenic sepsis was made. He was treated with intravenous imipenum, vancomycin, clindamycin, metronidazole and fluconazole. His serial blood cultures, urine cultures and sputum cultures were negative. His FBC was monitored twice daily throughout hospital stay, showed severe neutropenia and thrombocytopenia which later complicated by anemia from the 3rd day of hospital stay (Table 1; Fig. 1). The reticulocyte count was 1.1 % (normal 0.5–2.5). The patient was transferred to intensive care unit (ICU) on the 3rd day and treated with granulocyte colony stimulating factors (G-CSF) 300 µg daily for 10 days. On the 5th day he developed swelling of his left inguinal region with mild skin induration. The initial USS of left groin showed only subcutaneous tissue oedema. This subsequently progressed to an abscess which was drained. His white cell count and platelet count improved with 10 days of treatment with G-CSF. Hemoglobin normalized in 4 weeks of treatment. At this stage his WBC count was 12 × 103/µl with absolute neutrophil count 7200/µl (60 %), hemoglobin 12.6 g/dl and platelets 212 × 103/µl. He was started on conventional antipsychotics without clozapine for his psychiatric condition.
This case illustrates an extremely rare complication of pancytopenia caused by clozapine. Clozapine is known to cause agranulocytosis or neutropenia as a rare side effect. Approximately 2.7 % of patients treated with clozapine develop neutropenia, of which 0.9 % develops agranulocytosis . Most cases (50–80 %) occur during 18 weeks after commencing the treatment [3–5].
Baseline FBC should be routinely done before commencing clozapine and total WBC should be more than 4 × 103/µl with ANC more than 2.5 × 103/µl [5, 6]. It is recommended that weekly FBC should be done to detect blood dyscrasia early. The patient’s WBC count, at the time of starting clozapine was 7.7 × 103/µl with ANC 3927/µl (51 %), lymphocytes 3080/µl (40 %), eosinophils 462/µl (6 %), and platelets 260 × 103/µl. Hematological results are reported as ‘green’ (safe to continue treatment), ‘amber’ (borderline low or falling result) and ‘red’ (below the acceptable reference range). If the WBC subsequently drops below the ‘red’ cut-off of 3 × 103/µl or the neutrophil count falls below 1.5 × 103/µl, clozapine treatment must be stopped . In this patient pancytopenia was detected at 4 weeks of clozapine treatment and there were no blood counts done during this period.
There was only one reported case of 57-year-old male with clozapine induced pancytopenia who was subsequently managed with electroconvulsive therapy (ECT) . This patient was on clozapine for several years which was later combined with fluphenazine and promazine. He developed neutropenia after 1 year of combined antipsychotics therapy. Clozapine was stopped and restarted after 1 year and the patient had developed pancytopenia after about one and half year of therapy. His blood counts had spontaneously improved within 7 weeks after stopping clozapine. However In our patient the pancytopenia occurred within the first 4 weeks of treatment initiated with with clozapine.
Stübner et al. described the blood dyscrasias induced by psychotropic drugs after analyzing 122,562 patients in 35 psychiatric institutions since 1993–2000 . In this study, 107 cases of hematological changes had been documented with an incidence of 0.0873 %. Of these, pancytopenia was seen only in 2 and rest were neutropenia (63 cases), thrombocytopenia (16 cases), agranulocytosis (22 cases) and neutropenia thrombocytopenia (4 cases). Of these 2 cases of pancytopenia, both carbamazepine and lovastatin were rated as probable causative agents in combination in one case. In the other case, pancytopenia was observed during treatment with trimipramine. Clozapine induced pancytopenia was not observed in this study.
Recovery of blood dyscrasia usually occurs up to 4 weeks after clozapine withdrawal, but there were exceptions—in one case report thrombocytopenia and leucopenia both occurred during clozapine treatment and persisted for 13 weeks . Our patient recovered successfully from clozapine induced pancytopenia within 3 weeks. We emphasize that every patient who is started on clozapine need very close monitoring of FBC to detect blood dyscrasia to minimize serious complications.
Clozapine induced pancytopenia is extremely rare and periodic FBC should be done to detect blood dyscrasia early. We report an unusual and early complication of clozapine induced pancytopenia leading to severe sepsis recovered with antibiotics, granulocyte colony stimulating factors and supportive care.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
full blood count
white blood cell count
absolute neutrophil count
C reactive protein
ultra sound scan
granulocyte colony stimulating factors
intensive care unit
Whiskey E, Taylor D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs. 2007;21(1):25–35.
Voulgari C, et al. Clozapine-induced late agranulocytosis and severe neutropenia complicated with Streptococcus pneumonia, venous thromboembolism and allergic vasculitis in treatment-resistant female psychosis. Case Rep Med. 2015. doi:10.1155/2015/703218.
Lieberman JA. Maximizing clozapine therapy, managing side effects. J Clin Psychiatry. 1998;59(3):38–43.
Ahmad N, Rosli Md, Subbiah R, Maniam T. Clozapine re-challenge with lithium supplementation following clozapine-induced neutropenia. Asian J Psychiatry. 2014;15(1):90–2.
Suraweera C, Hanwella R, de Silva V. Use of lithium in clozapine-induced neutropenia: a case report. BMC Res Notes. 2014;7:635.
Paton C, Esop R. Managing clozapine-induced neutropenia with lithium. Psychiatr Bull. 2005;29:186–8.
Jovanovi N, Lovreti V, Kuzman MR. The use of electroconvulsive therapy and general anaesthesia in catatonic schizophrenia complicated by clozapine-induced pancytopenia-case report. Psychiatr Danub. 2014;26(3):285–7.
Stübner S, et al. Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry. 2004;37(suppl 1):S70–8.
All authors were involved in the management of the patient. JP researched the background literature on the case and wrote the first draft. AL and JI contributed towards the discussions and analysis of the case. All authors read and approved the final manuscript.
JP (MBBS) is a Registrars in Internal Medicine, PK (MBBS) is a Registrar in Hematology, SS (MBBS, MD) Senior Registrar in Internal Medicine, University Medical Unit, Colombo South Teaching Hospital, Kalubowila, Sri Lanka. AL (MBBS, MD, MRCP) is a Consultant Physician and Senior Lecturer in Medicine, JI (MBBS, MD, FRCP) is a Professor in Medicine and consultant physician, in the Department of Medicine, Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka.
The authors declare that they have no competing interests.